Technology ID
TAB-2517
Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis
E-Numbers
E-070-2012-0
Lead Inventor
Kim, Hee-Yong (National Institute on Alcohol Abuse and Alcoholism (NIAAA))
Co-Inventors
Englund, Erika (NCATS)
Marugan, Juan (National Human Genome Research Institute (NIH/NHGRI))
Patnaik, Samarjit (National Human Genome Research Institute (NIH/NHGRI))
Applications
Vaccines
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Reproductive Health
Neurology
Development Stages
Discovery
Development Status
- Early-stage
- In vitro data available
- Prototype
Lead IC
NIAAA
ICs
NCATS
The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid accumulates in the brain during development, and has been implicated in learning and memory development. DEA, a metabolite derived from DHA, also has been shown to accelerate neuronal growth and development. In vitro studies in which neural progenitor cells were treated with DEA derivatives showed an increase in the number of somatic neurons produced after differentiation.
Commercial Applications
- Neurogenesis
- Neurite growth
- Synaptogenesis
- Therapeutics for traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
Competitive Advantages
- These derivatives of DEA provide increased potency and hydrolysis resistance compared to DEA.
Licensing Contact: